Towards Healthcare
Clinical Genomics Market Soars at 17.54% CAGR by 2034

Clinical Genomics Market Growth and Opportunities

Projections indicate that, the global clinical genomics market will increase from USD 1.06 billion in 2024 to USD 5.34 billion by 2034, experiencing a CAGR of 17.54% over the next 10 years. The clinical genomics market is expanding due to growing occurrences of genetic and rare diseases as well as rising advancements in molecular diagnostic testing. North America led the market due to the presence of the advanced healthcare sector. 

Content

  • Last Updated: 01 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The market is growing at a CAGR of 17.54% (2025–2034), driven by rising cases of genetic and rare diseases, rapid advancements in molecular diagnostics (like NGS and CRISPR), and increasing integration of AI in personalized and precision medicine

With the market projected to grow from US$ 1.25 billion in 2025 to US$ 5.34 billion by 2034, the sector presents a strong investment case.

AI is transforming clinical genomics by enabling rapid genomic data interpretation, enhancing phenotype predictions, improving precision in drug discovery, and personalizing treatment pathways

Asia Pacific is expected to be the fastest-growing region due to expanding healthcare infrastructure, increasing R&D investments, and rising awareness of genetic diseases.

Next-generation sequencing (NGS), liquid biopsy, CRISPR-based diagnostics, and AI-integrated analysis platforms are key trends.

High costs, complex data interpretation, limited reimbursement models, and a shortage of skilled professionals are key challenges.

Collaborations-such as Illumina & Nashville Biosciences AGD initiative and GenePoweRx AI alliances—are pivotal.

While stringent, evolving regulations are ensuring high accuracy and patient safety, they can delay product launches and increase operational costs.

Leaders include Illumina, Quest Diagnostics, PerkinElmer, Invitae, Myriad Genetics, Natera, and Eurofins.

The future is bright with increasing adoption in routine clinical settings, advancements in personalized therapies, and growing public-private funding.
Any Questions